Literature DB >> 17545581

Mechanism and therapeutic reversal of immune suppression in cancer.

Donna L Herber1, Srinivas Nagaraj, Julie Y Djeu, Dmitry I Gabrilovich.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 17545581      PMCID： PMC1976287          DOI： 10.1158/0008-5472.CAN-07-0897

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  14 in total

Review 1.  Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.

Authors:  Hua Yu; Marcin Kortylewski; Drew Pardoll
Journal:  Nat Rev Immunol       Date:  2007-01       Impact factor: 53.106

Review 2.  Immunotherapy for pancreatic cancer - science driving clinical progress.

Authors:  Dan Laheru; Elizabeth M Jaffee
Journal:  Nat Rev Cancer       Date:  2005-06       Impact factor: 60.716

Review 3.  Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression.

Authors:  Paolo Serafini; Ivan Borrello; Vincenzo Bronte
Journal:  Semin Cancer Biol       Date:  2005-09-15       Impact factor: 15.707

Review 4.  The role of stroma in immune recognition and destruction of well-established solid tumors.

Authors:  Ping Yu; Donald A Rowley; Yang-Xin Fu; Hans Schreiber
Journal:  Curr Opin Immunol       Date:  2006-02-03       Impact factor: 7.486

Review 5.  Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression.

Authors:  Pratima Sinha; Virginia K Clements; Seth Miller; Suzanne Ostrand-Rosenberg
Journal:  Cancer Immunol Immunother       Date:  2005-05-05       Impact factor: 6.968

Review 6.  Mechanisms and functional significance of tumour-induced dendritic-cell defects.

Authors:  Dmitry Gabrilovich
Journal:  Nat Rev Immunol       Date:  2004-12       Impact factor: 53.106

Review 7.  Cancer vaccines: between the idea and the reality.

Authors:  Olivera J Finn
Journal:  Nat Rev Immunol       Date:  2003-08       Impact factor: 53.106

Review 8.  Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation.

Authors:  David H Munn
Journal:  Curr Opin Immunol       Date:  2006-02-07       Impact factor: 7.486

9.  Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer.

Authors:  Scott J Antonia; Noweeda Mirza; Ingo Fricke; Alberto Chiappori; Patricia Thompson; Nicholas Williams; Gerold Bepler; George Simon; William Janssen; Ji-Hyun Lee; Kerstin Menander; Sunil Chada; Dmitry I Gabrilovich
Journal:  Clin Cancer Res       Date:  2006-02-01       Impact factor: 12.531

Review 10.  Immunoregulatory T cells in tumor immunity.

Authors:  Masaki Terabe; Jay A Berzofsky
Journal:  Curr Opin Immunol       Date:  2004-04       Impact factor: 7.486
View more
  20 in total

Review 1.  A pharmacologic perspective on newly emerging T-cell manipulation technologies.

Authors:  Dominic Smethurst
Journal:  Br J Clin Pharmacol       Date:  2013-08       Impact factor: 4.335

2.  Mesenchymal Stem Cells Overexpressing IFN-β Inhibit Breast Cancer Growth and Metastases through Stat3 Signaling in a Syngeneic Tumor Model.

Authors:  Xiaoyang Ling; Frank Marini; Marina Konopleva; Wendy Schober; Yuexi Shi; Jared Burks; Karen Clise-Dwyer; Rui-Yu Wang; Weiguo Zhang; Xiaoqing Yuan; Hongbo Lu; Lisa Caldwell; Michael Andreeff
Journal:  Cancer Microenviron       Date:  2010-03-19

3.  Interleukin-6 affects cell death escaping mechanisms acting on Bax-Ku70-Clusterin interactions in human colon cancer progression.

Authors:  Sabina Pucci; Paola Mazzarelli; Mazzarelli Paola; Fabiola Sesti; Sesti Fabiola; David A Boothman; Boothman A David; Luigi G Spagnoli; Spagnoli G Luigi
Journal:  Cell Cycle       Date:  2009-02-18       Impact factor: 4.534

4.  Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade.

Authors:  Karsten A Pilones; Noriko Kawashima; Anne Marie Yang; James S Babb; Silvia C Formenti; Sandra Demaria
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

5.  Engulfing tumors with synthetic extracellular matrices for cancer immunotherapy.

Authors:  Yuki Hori; Patrick J Stern; Richard O Hynes; Darrell J Irvine
Journal:  Biomaterials       Date:  2009-09-19       Impact factor: 12.479

6.  Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody.

Authors:  M Zahidunnabi Dewan; Ashley E Galloway; Noriko Kawashima; J Keith Dewyngaert; James S Babb; Silvia C Formenti; Sandra Demaria
Journal:  Clin Cancer Res       Date:  2009-08-25       Impact factor: 12.531

7.  Alterations of dendritic cell subsets and TH1/TH2 cytokines in the peripheral circulation of patients with superficial transitional cell carcinoma of the bladder.

Authors:  Feng Lang; Ma Linlin; Tian Ye; Zhang Yuhai
Journal:  J Clin Lab Anal       Date:  2012-09       Impact factor: 2.352

Review 8.  Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy.

Authors:  Junjie Wu; David J Waxman
Journal:  Cancer Lett       Date:  2018-04-10       Impact factor: 8.679

9.  Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma.

Authors:  Taylor J Brueseke; Krishnansu S Tewari
Journal:  Clin Pharmacol       Date:  2013-05-23

10.  Reduction of splenic immunosuppressive cells and enhancement of anti-tumor immunity by synergy of fish oil and selenium yeast.

Authors:  Hang Wang; Yi-Lin Chan; Tsung-Lin Li; Brent A Bauer; Simon Hsia; Cheng-Hsu Wang; Jen-Seng Huang; Hung-Ming Wang; Kun-Yun Yeh; Tse-Hung Huang; Gwo-Jang Wu; Chang-Jer Wu
Journal:  PLoS One       Date:  2013-01-22       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.